

# Special Issue

## New Insights in Thyroid Cancer

### Message from the Guest Editor

Thyroid cancer is the most common endocrine malignancy, and its incidence has increased significantly worldwide in recent decades.

Recent years have seen the introduction of novel therapies, including multi-kinase inhibitors, selective RET inhibitors, and immunotherapeutic approaches, many of which are under clinical investigation or in use.

The upcoming Special Issue, “New Insights in Thyroid Cancer”, aims to present the latest findings and advances in thyroid cancer research from basic science to clinical application. We invite researchers and clinicians to submit contributions that explore new concepts in thyroid cancer diagnosis, treatment, and disease mechanisms.

Topics of interest include (but are not limited to) the following:

Molecular and genetic mechanisms of thyroid tumorigenesis;

Novel biomarkers for diagnosis, prognosis, and treatment responses;

Advances in imaging and diagnostic techniques;

Targeted therapies and resistance mechanisms;

Immunotherapy and its role in thyroid cancer;

Active surveillance and individualized management strategies.

---

### Guest Editor

Dr. Rodis D. Paparodis

1. Hellenic Endocrine Network, 105 63 Athens, Greece
2. Loyola University Medical Center, Maywood, IL 60153, USA
3. Edward Hines Jr. VA Hospital, Hines, IL 60141, USA

---

### Deadline for manuscript submissions

31 March 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/250748](https://mdpi.com/si/250748)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).